Abstract:Introduction: MRI-guided focused ultrasound (FUS) is an incisionless thermo-ablative procedure that may be used to treat medication-refractory movement disorders, with a growing number of potential anatomic targets and clinical applications. As of this article’s publication, the only US Food and Drug Administration (FDA)-approved uses of FUS for movement disorders are thalamotomy for essential tremor (ET) and tremor-dominant Parkinson’s Disease (PD), and pallidotomy for other cardinal symptoms of PD. We present a state-of-the-art review on all non-FDA approved indications of FUS for movement disorders, beyond the most well-described indications of ET and PD. Our objective was to summarize the safety and efficacy of FUS in this setting and provide a roadmap for future directions of FUS for movement disorders. Methods: A state-of-the-art review was conducted on use of FUS for non-FDA approved movement disorders. All movement disorders excluding FDA-approved uses for ET and PD were included. Results: A total of 25 studies on 172 patients were included. In patients with tremor plus dystonia syndromes ( n = 6), ventralis intermediate nucleus of the thalamus (VIM)-FUS gave >50% tremor reduction, with no improvement in dystonia and worsened dystonia in 2/6 patients. Ventral-oralis complex (VO)-FUS gave >50% improvement for focal hand dystonia ( n = 6) and 100% return to musical performance in musician’s dystonia ( n = 6). In patients with multiple sclerosis (MS) and tremor ( n = 3), improvement in tremor was seen in 2 patients with a favorable skull density ratio; no MS disease change was noted after VIM-FUS. In patients with tremor and comorbid ataxia syndromes ( n = 3), none were found to have worsened ataxia after VIM-FUS; all had clinically significant tremor improvement. Subthalamic nucleus (STN)-FUS for PD ( n = 49) gave approximately 50% improvement in PD motor symptoms, with dystonia and mild dyskinesias as possible adverse effects. Cerebellothalamic tract (CTT-FUS) for ET ( n = 42) gave 55–90% tremor improvement, with gait dysfunction as a rare persistent adverse effect. Pallidothalamic tract (PTT-FUS) for PD ( n = 50) gave approximately 50% improvement in motor symptoms, with mild speech dysfunction as a possible adverse effect. Conclusion: VIM-FUS appeared safe and effective for heterogenous tremor etiologies, and VO-FUS appeared most effective for isolated segmental dystonia. STN-FUS was effective for PD symptom reduction; postoperative dystonia and mild on-medication dyskinesias required medical management. Tractography-based targeting with CTT-FUS for ET and PTT-FUS for PD demonstrated promising early results. Larger prospective trials with long-term follow-up are needed to the evaluate the safety and efficacy non-FDA approved indications for FUS.

The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease

Focused ultrasound in Parkinson's disease: A twofold path toward disease modification

First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease

The Use of Focused Ultrasound Ablation for Movement Disorders

Clinical application of magnetic resonance-guided focused ultrasound in Parkinson’s disease: a meta‐analysis of randomized clinical trials

Focused Ultrasound for Treatment of Movement Disorders: A Review of Non-Food and Drug Administration Approved Indications

Focused ultrasound opening of the blood–brain barrier for treatment of Parkinson's disease

Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkisnsonism

Unilateral Magnetic Resonance–Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study

Stepwise dual‐target magnetic resonance‐guided focused ultrasound in tremor‐dominant Parkinson disease: One‐year follow‐up

Staged magnetic resonance-guided focused ultrasound thalamotomy for the treatment of bilateral essential tremor and Parkinson's disease related tremor: a systematic review and critical appraisal of current knowledge

MR-guided focused ultrasound in movement disorders and beyond: Lessons learned and new frontiers

Probabilistic Refinement of Focused Ultrasound Thalamotomy Targeting for Parkinson's Disease Tremor

Focused ultrasound therapy in movement disorders: management roadmap towards optimal pathway organization

Focused Ultrasound Thalamotomy for Tremor Treatment Impacts the Cerebello-Thalamo-cortical Network

The emerging role of transcranial magnetic resonance imaging-guided focused ultrasound in functional neurosurgery

Safety and efficacy of unilateral focused ultrasound pallidotomy on motor complications in Parkinson's disease (PD): a systematic review and meta-analysis

Preliminary observation of transcranial MR-guided focused ultrasound in the treatment of tremor related to Parkinson’s disease

Focused ultrasound thalamotomy location determines clinical benefits in patients with essential tremor

Focused Ultrasound: An Emerging Therapeutic Modality for Neurologic Disease

3-T MR-guided focused ultrasound thalamotomy for tremor in patients with a cardiac pacemaker: case series and review of the literature